6533b86dfe1ef96bd12c9787

RESEARCH PRODUCT

Magnetic Resonance Imaging Derived Biomarkers of IDH Mutation Status and Overall Survival in Grade III Astrocytomas

Riccardo PertileLuc Van Den HauwePatrizia FerrazzaAlessio G. MorgantiCesare GagliardoAntonella BacciSalvatore GirlandoBenedetto PetraliaMattia BarbareschiPaola Feraco

subject

medicine.medical_specialtyoverall survivalClinical BiochemistryradiogenomicsRadiogenomicsGastroenterologyArticle03 medical and health sciences0302 clinical medicineGliomaInternal medicinemedicineOverall survivalEffective diffusion coefficientdiffusion weighted imaging (DWI)apparent diffusion coefficient (ADC)lcsh:R5-920medicine.diagnostic_testbusiness.industryanaplastic astrocytomaMagnetic resonance imagingmedicine.diseaseExact testIsocitrate dehydrogenaseisocitrate dehydrogenase (IDH) mutation030220 oncology & carcinogenesisHuman medicinelcsh:Medicine (General)businessanaplastic astrocytomas030217 neurology & neurosurgeryAnaplastic astrocytoma

description

The evaluation of the isocitrate dehydrogenase (IDH) mutation status in the glioma decision-making process has diagnostic, prognostic and therapeutic implications. The aim of this study was to evaluate whether conventional magnetic resonance imaging (MRI) and apparent diffusion coefficient (ADC) can noninvasively predict the most common IDH mutational status (R132H) in GIII-astrocytomas and the overall survival (OS). Hence, twenty-two patients (9-F, 13-M) with a histological diagnosis of GIII-astrocytoma and evaluation of IDH-mutation status (12-wild type, 10-mutant) were retrospectively evaluated. Imaging studies were reviewed for the morphological feature and mean ADC values (ADCm). Statistics included a Fisher&rsquo

yearjournalcountryeditionlanguage
2020-04-01Diagnostics
10.3390/diagnostics10040247http://dx.doi.org/10.3390/diagnostics10040247